Jolanta Maria Siller-Matula

Associate Professor

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jolanta Maria Siller-Matula is an Associate Professor at the Medical University of Vienna, Austria. Her research focuses on antithrombotic therapies, particularly in the context of acute coronary syndromes and women's health in clinical trials. Recent publications include studies on bleeding complications in cardiac arrest patients and the management of congenital bleeding disorders. She is actively involved in developing clinical consensus guidelines and predictive models related to cardiovascular diseases.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (28)

Jorge Ferreira

MD, Head of Inpatient Unit

PORTUGAL

Jolanta Maria Siller-Matula

Research Interests

Explore related searches

Contact this professor

About

Articles (25)

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy

Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors.

Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.

Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.

Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).

2023 ESC Guidelines for the management of acute coronary syndromes

Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

Prediction model for leaflet thrombosis in patients undergoing transcatheter aortic valve implantation: the EFFORT study.

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

2023 ESC Guidelines for the management of acute coronary syndromes

Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials

Effects of empagliflozin in women and men with acute myocardial infarction – an analysis from the EMMY trial

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

Clinical outcomes associated with type II myocardial infarction caused by bleeding.

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis

Corrigendum to 'Outcomes of Percutaneous Coronary Intervention in Patients With Acquired Immunosuppression' The American Journal of Cardiology Volume 171, 15 May 2022, Pages 40-48.

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis.

Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis.

Empagliflozin in acute Myocardial Infarction: the EMMY trial.

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease.

Sex Differences in Clinical Profile and Outcome After Percutaneous Coronary Intervention for Chronic Total Occlusion.

Collaborators (28)

Jorge Ferreira

Dan Atar

Marek Postula

Kern Adam

Ewald Kolesnik

Aleksandra Gąsecka

Anselm Jorda

Felix Bergmann

Marc R Dweck

Paulus Kirchhof

Diana Gorog

Julia Uminska

Renate B. Schnabel

Arthur Hosmann

Ruben Casado Arroyo

Lucia Torracca

Young-Hoon Jeong

Anna Nowak-Szwed

Bruna Gigante

Philippe Meyer

RICCARDO ASTEGGIANO

Bernd Jilma

Faisal Aziz

Ewa A Jankowska

Radosław Lenarczyk

Pietro Ameri

Xavier Rossello

Ceren Eyileten

Make your next move.